Genmab A/S

402 articles with Genmab A/S

• Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

  5/12/2022

  Genmab A/S announced that multiple abstracts evaluating epcoritamab, an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association Annual Congress, being held in Vienna, Austria, and virtually, June 9-12.

• Genmab Announces Financial Results for the First Quarter of 2022

  5/11/2022

  Genmab Announces Financial Results for the First Quarter of 2022.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022

  4/19/2022

  Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD1,856million in the first quarter of 2022.

• AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

  4/13/2022

  AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical trial evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody.

• Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

  4/7/2022

  Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab.

• Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma

  3/8/2022

  Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL).

• Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

  2/24/2022

  Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck.

• Notice to Convene the Annual General Meeting of Genmab A/S

  2/24/2022

  COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, KalvebodBrygge 5, DK-1560 Copenhagen V, Denmark.

• Genmab Publishes 2021 Annual Report

  2/16/2022

  Genmab A/S announced the publication of its Annual Report for 2021.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021

  1/25/2022

  Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 6,023 million in 2021.

• Genmab and Synaffix Enter into License Agreement for ADC Technology

  1/4/2022

  Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.

• 

  Janssen and Amgen Combine for Regulatory Win in Multiple Myeloma

  12/1/2021

  The approval was based on Phase II data from the PLEIADES study that showed patients treated with the combination therapy generated an overall response rate of 84.8%.

• Genmab Announces Financial Results for the First Nine Months of 2021

  11/10/2021

  Genmab Announces Financial Results for the First Nine Months of 2021

• 

  Novartis Walks Away from $2.6 Billion Xencor Collaboration

  11/9/2021

  Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.

• Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

  11/4/2021

  Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

• Genmab Improves its 2021 Financial Guidance

  11/4/2021

  Genmab A/S announced that it is improving its 2021 financial guidance published on August 11, 2021.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

  10/19/2021

  Copenhagen, Denmark; October 19, 2021 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,580million in the third quarter of 2021.

• 

  FDA Action Alert: Takeda, ChemoCentryx, Genmab and Seagen, and Avadel

  10/4/2021

  The U.S. FDA is kicking off the month of October with a number of PDUFA dates and an advisory committee meeting. Read on for more details.
• 

  Clinical Catch-Up: September 20-24

  9/27/2021

  There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.

• Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

  9/20/2021

  Seagen Inc. and Genmab A/S announced that the U.S. Food and Drug Administration has granted accelerated approval to TIVDAK™, the first and only approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.